Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in ovarian cancer
- Trial result Spotlight
Ovarian cancer
Sofetabart mipitecan (FRα-targeted ADC) posts 50.5% ORR and 8.1-mo mPFS in heavily pretreated HGOC—without keratopathy
Sofetabart mipitecan (Sofe-M) is an FRα-targeting antibody–drug conjugate engineered to broaden activity beyond “FRα-high only” tumors and potentially avoid the ocular toxicity seen with mirvetuximab soravtansine…
NCT07213804 - New trial Spotlight
Ovarian cancer
Phase 3 TREVI-OC-02 tests FRα-targeted torvutatug samrotecan plus bevacizumab maintenance in HRD-negative ovarian cancer
AstraZeneca’s TREVI-OC-02 is a randomized, open-label Phase 3 trial comparing torvutatug samrotecan (torvu-sam) plus bevacizumab with bevacizumab alone as first-line maintenance. Torvu-sam is a folate receptor alpha…
NCT07851025 Registrational - New trial
Ovarian cancer
Phase 2 NRG-GY038 compares sacituzumab govitecan plus bevacizumab with platinum-based treatment after PARP-inhibitor progression
This randomized Phase 2 NCI/NRG Oncology study tests sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) plus bevacizumab against carboplatin and pegylated liposomal doxorubicin, or protocol-allowed gemcitabine,…
NCT07504588 Exploratory - New trial
Ovarian cancer
Phase 3 REJOICE-Ovarian04 tests CDH6-targeted raludotatug deruxtecan maintenance with or without bevacizumab
Merck Sharp & Dohme is running this randomized, open-label Phase 3 study of raludotatug deruxtecan (R-DXd; MK-5909), a CDH6-directed antibody-drug conjugate developed with Daiichi Sankyo that delivers a topoisomerase…
NCT07776691 Registrational - New trial Spotlight
Ovarian cancer
Phase 3 torvutatug samrotecan FRα (FOLR1) ADC with exatecan (topoisomerase I) payload
AstraZeneca’s TREVI-OC-03 is a randomized, open-label Phase 3 maintenance study testing torvutatug samrotecan (torvu-sam; AZD5335), a folate receptor alpha (FRα/FOLR1)–directed monoclonal antibody–drug conjugate…
NCT07816666 Registrational - New trial
Ovarian cancer
Phase 2 atorvastatin HMG‑CoA reductase inhibitor immunometabolism add‑on in HGSOC
This University of Colorado Denver–sponsored Phase 2, randomized “window/add-on” study asks whether adding daily atorvastatin (a small‑molecule HMG‑CoA reductase inhibitor that alters cholesterol/mevalonate…
NCT07815704 Exploratory - Trial result Spotlight
Ovarian cancer
Pembrolizumab (PD-1) + chemo → maintenance pembrolizumab + olaparib (PARP) extends PFS in BRCA–wild-type ovarian cancer
Pembrolizumab is an anti–PD-1 antibody and olaparib is a PARP inhibitor; in KEYLYNK-001 (ENGOT-OV43/GOG-3036; NCT03740165), patients with newly diagnosed stage III–IV BRCA1/2 non-mutated epithelial ovarian/primary…
NCT03740165 - New trial
Ovarian cancer
Phase 2 sacituzumab tirumotecan (MK-2870) TROP2 ADC ± pembrolizumab PD-1 mAb in OCCC
This randomized Phase 2 study at Tufts Medical Center tests sacituzumab tirumotecan (MK-2870), a TROP2-directed antibody-drug conjugate that delivers a belotecan-derived topoisomerase I–inhibitor payload, either…
NCT07718854 Exploratory - Trial result
Ovarian cancer
Darolutamide (androgen receptor inhibitor) + leuprolide + exemestane shows low ORR but 8.5-mo mPFS in AI-refractory recurrent AGCT
Darolutamide is an oral androgen receptor (AR) antagonist combined here with ovarian suppression (leuprolide acetate) plus steroidal aromatase inhibition (exemestane) in a single-arm Phase II cooperative group study…
NCT06169124 - New trial
Ovarian cancer
Phase 1 arginine supplementation metabolic immunomodulator with pembrolizumab PD-1 blockade in PROC
This open-label, non-randomized Phase 1 study tests whether supplemental L-arginine (oral and/or IV) can safely be added to common chemoimmunotherapy backbones for high-grade, platinum-resistant ovarian/fallopian…
NCT07772882 Exploratory - New trial
Ovarian cancer
Phase 1b/2 TUB-040 NaPi2b-targeted topoisomerase I inhibitor (exatecan) ADC + Carbo/Bev
This multicenter Phase 1b/2 study evaluates TUB-040 (Tubulis GmbH)—a NaPi2b-directed antibody–drug conjugate delivering the topoisomerase I inhibitor payload exatecan via a cleavable linker—combined with carboplatin…
NCT07736937 Exploratory - New trial
Ovarian cancer
Phase 2 OVAFIT-TIL CD137 (4-1BB)–selected autologous TIL + PD-1 blockade
This Phase 2 study at the Medical University of South Carolina (MUSC) tests an autologous tumor-infiltrating lymphocyte (TIL) product that is metabolically optimized and enriched for CD137+ (4-1BB+) activated T…
NCT07720180 Exploratory - New trial Spotlight
Ovarian cancer
Phase 1 ARR-002 dual-target MUC16/NaPi2b ADC (vcMMAE microtubule inhibitor payload) in ovarian/endometrial cancer.
This first-in-human, open-label, multicenter Phase 1a/1b dose-escalation/expansion study evaluates ARR-002 in adults with locally advanced or metastatic ovarian or endometrial cancer. ARR-002 (ArriVent BioPharma) is…
NCT07755436 First-in-human - Trial result
Ovarian cancer
Darolutamide (AR antagonist) + leuprolide + exemestane misses ORR bar but delivers 8.5-mo mPFS in AI-refractory recurrent AGCT
Darolutamide is an androgen receptor (AR) antagonist combined here with ovarian suppression (leuprolide acetate, a GnRH agonist) and estrogen blockade (exemestane, a steroidal aromatase inhibitor) in a single-arm…
NCT06169124 - New trial Spotlight
Ovarian cancer
Phase 3 rinatabart sesutecan (Rina-S) FRα ADC delivering exatecan (topoisomerase I inhibitor)
Genmab’s open-label, randomized Phase 3 trial (NCT07564141; ~688 participants planned) tests rinatabart sesutecan (Rina-S)—a folate receptor alpha (FRα/FOLR1)–directed antibody-drug conjugate that delivers an…
NCT07564141 Registrational - New trial
Ovarian cancer
Phase 1 NTB-928 FRα×CD3 bispecific T-cell engager in relapsed/refractory ovarian carcinoma.
This Phase 1, multicenter, open-label dose-escalation and expansion study tests NTB-928, a fully human FRα (FOLR1)×CD3 bispecific T-cell engager antibody that redirects T cells to kill FRα-overexpressing tumor cells.…
NCT07690189 First-in-human - Trial result Spotlight
Ovarian cancer
Rezatapopt (p53 Y220C reactivator) drives 46% ORR in heavily pretreated TP53 Y220C ovarian cancer
Rezatapopt is an oral, first-in-class small-molecule “p53 reactivator” that selectively binds mutant TP53 Y220C, stabilizes p53 in a wild-type–like conformation, and aims to restore tumor-suppressor function. In the…
NCT04585750 - Trial result Spotlight
Ovarian cancer
Fulvestrant + abemaciclib enables cytoreduction in unresectable LGSOC
Fulvestrant is an intramuscular selective estrogen receptor degrader, and abemaciclib is an oral CDK4/6 inhibitor targeting ER-driven cell-cycle signaling. In a pilot Phase 2 neoadjuvant study in advanced, initially…
NCT03531645 - Trial result
Ovarian cancer
KRAS-mutant mesonephric-like ovarian adenocarcinoma shows 17.5-mo median PFS and “cotton candy” ultrasound signature
Mesonephric-like adenocarcinoma (MLA) is a rare ovarian carcinoma subtype (WHO 2020) that appears molecularly KRAS-driven; in this prospective, single-center observational series (Jan 2020–Dec 2023), 14/467 ovarian…
- Trial result Spotlight
Ovarian cancer
Azenosertib (WEE1 inhibitor) + weekly paclitaxel delivers 39% ORR in platinum-resistant ovarian cancer
Azenosertib (ZN-c3) is an oral, selective WEE1 kinase inhibitor designed to exploit replication stress and impair DNA-damage checkpoint control; in the MUIR Phase 1b open-label dose-escalation trial (NCT04516447), it…
NCT04516447 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel extends OS by 4.1 months in platinum-resistant ovarian cancer
Relacorilant is a first-in-class, selective glucocorticoid receptor (GR) antagonist intended to counter GR-mediated chemotherapy resistance, and was combined with weekly nab-paclitaxel in the Phase 3 ROSELLA trial…
NCT05257408 - Trial result Spotlight
Ovarian cancer
TUB-040 (NaPi2b Exatecan ADC) Delivers 61% cORR in Platinum-Resistant Ovarian Cancer
TUB-040 is a NaPi2b-targeted antibody–drug conjugate with a DAR8 exatecan topoisomerase I payload via a cleavable P5 linker, evaluated as every-3-week monotherapy in biomarker-unselected platinum-resistant ovarian…
NCT06303505 - Trial result
Ovarian cancer
SBS5 (clock-like) mutational signature flags longer PFS after cisplatin HIPEC in EOC
In a single-center WES biomarker analysis of patients with primary or recurrent epithelial ovarian cancer (EOC) treated with cisplatin HIPEC during optimal cytoreductive surgery (cisplatin 75mg/m², 60 min, 42°C;…
NCT01970722 - Trial result
Ovarian cancer
Delayed interval debulking (6-cycle NAC) shows no DFS gain vs standard 3-cycle timing in CHRONO ovarian cancer
CHRONO (NCT03579394) tested whether delaying complete cytoreductive surgery after neoadjuvant platinum-taxane chemotherapy improves outcomes in FIGO stage IIIB–IVA high-grade epithelial ovarian cancer that was deemed…
NCT03579394 - Trial result
Ovarian cancer
Mirvetuximab soravtansine (FRα ADC) + carboplatin fails to improve PFS vs standard platinum doublets in FRα-high recurrent ovarian cancer
Mirvetuximab soravtansine (MIRV) is an FRα-targeted antibody–drug conjugate delivering the maytansinoid payload DM4; in MIROVA/AGO-OVAR 2.34 (Phase II; NCT04274426), platinum-eligible recurrent ovarian cancer with…
NCT04274426 - Trial result
Ovarian cancer
Sacituzumab govitecan (TROP2 ADC delivering SN-38) posts 35% ORR and 8.0‑mo mPFS in platinum‑resistant ovarian cancer
Sacituzumab govitecan (SG) is a TROP2-directed antibody–drug conjugate that delivers SN-38 (irinotecan’s active metabolite) to TROP2-expressing tumor cells; in this single-institution, open-label Phase II study…
NCT06028932 - Trial result
Ovarian cancer
ETX-19477 (oral PARG inhibitor) posts 29% PR rate in heavily pretreated BRCA-mut HGSOC
ETX-19477 is an oral, potent, selective poly(ADP-ribose) glycohydrolase (PARG) inhibitor designed to exploit replication-fork DNA repair vulnerabilities (mechanistically distinct from PARP inhibitors). In the…
NCT06395519 - Trial result
Ovarian cancer
BI-1808 (TNFR2 IgG1 mAb; Treg-depleting) + pembrolizumab delivers 24% ORR in heavily pretreated ovarian cancer
BI-1808 is an anti-TNFR2 IgG1 monoclonal antibody designed to block TNF-α/TNFR2 signaling and, via FcγR engagement, deplete tumor Tregs and reprogram myeloid cells—mechanistically complementary to PD-1 blockade with…
NCT04752826 - Trial result
Ovarian cancer
YL205 (NaPi2b-targeted topo1 ADC) posts 46.5% ORR in heavily pretreated ovarian cancer
YL205 is a NaPi2b-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (TMALIN platform) evaluated as monotherapy in the first-in-human, multicenter, open-label Phase I/II YL205-CN-101-01…
NCT06459973 - New trial Spotlight
Ovarian cancer
Phase 1 GB-5267 IL-18–armored anti-MUC16 CAR T cell therapy in platinum-resistant ovarian cancer.
This first-in-human, open-label Phase 1 dose-escalation study tests GB-5267, an autologous CAR T-cell product engineered to recognize MUC16 (a surface antigen commonly expressed in epithelial ovarian cancers) and…
NCT07489287 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.